-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Friday's After-Market Session
Share
Listen to the news

Gainers

  • Virax Biolabs Group (NASDAQ:VRAX) stock moved upwards by 70.3% to $0.18 during Friday's after-market session. The company's market cap stands at $1.0 million.
  • IDEAYA Biosciences (NASDAQ:IDYA) stock increased by 18.81% to $36.24. The market value of their outstanding shares is at $2.7 billion.
  • Allogene Therapeutics (NASDAQ:ALLO) shares moved upwards by 13.6% to $3.09. The company's market cap stands at $709.3 million.
  • Oncolytics Biotech (NASDAQ:ONCY) shares rose 7.52% to $1.0. The company's market cap stands at $111.9 million.
  • PureTech Health (NASDAQ:PRTC) shares increased by 6.51% to $17.5. The market value of their outstanding shares is at $400.1 million.
  • PharmaCyte Biotech (NASDAQ:PMCB) shares moved upwards by 6.38% to $0.69. The company's market cap stands at $7.2 million.

Losers

  • Wellgistics Health (NASDAQ:WGRX) shares declined by 9.9% to $0.11 during Friday's after-market session. The market value of their outstanding shares is at $12.7 million.
  • Nasus Pharma (AMEX:NSRX) stock declined by 7.1% to $2.04. The company's market cap stands at $27.1 million.
  • Vivos Therapeutics (NASDAQ:VVOS) shares fell 6.62% to $1.13. The company's market cap stands at $13.7 million.
  • Estrella Immunopharma (NASDAQ:ESLA) shares fell 6.53% to $1.72. The company's market cap stands at $78.9 million.
  • Geovax Labs (NASDAQ:GOVX) shares decreased by 6.51% to $1.15. The company's market cap stands at $2.5 million.
  • Profusa (NASDAQ:PFSA) shares fell 6.36% to $0.81. The company's market cap stands at $1.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending